Aging
Navigate
Submit an Article
Research Paper|Volume 14, Issue 12|pp. 5223–5232
The efficacy of adding hyperthermia to the treatment of advanced NSCLC patients based on the states of EGFR
Back to articleFigure 2(2 of 4)
100%
Figure 2
Figure 2.The subgroups analysis of non-EGFR mutation between two groups. (A) 1-year OS rates of non-EGFR mutation between two groups (P<0.05). (B) 1-year PFSfirst rates of non-EGFR mutation between two groups (P<0.01).
Figure 2 — The efficacy of adding hyperthermia to the treatment of advanced NSCLC patients based on the states of EGFR | Aging